Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Randomized Multi-Centre Trial, Comparing Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 3 Days, Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 48 Hours and Artemether-Lumefantrine FDC Over 3 Days on P. Falciparum Malaria

NCT00484900 is registered in ClinicalTrials.gov with Dafra Pharma as lead sponsor.

NCT NCT00484900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00484900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Randomized Multi-Centre Trial, Comparing Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 3 Days, Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 48 Hours and Artemether-Lumefantrine FDC Over 3 Days on P. Falciparum Malaria
Lead sponsor
Dafra Pharma
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2006
Completion date
May 31, 2007
Enrollment
1,390 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

plasmodium falciparum malaria